Mesoblast Ltd (MSB)

1.010
-0.025(-2.42%)
  • Volume:
    1,041,444
  • Bid/Ask:
    1.010/1.015
  • Day's Range:
    0.995 - 1.030

MSB Overview

Prev. Close
1.035
Day's Range
0.995-1.03
Revenue
13.62M
Open
1.02
52 wk Range
0.965-2.34
EPS
-0.22
Volume
1,041,444
Market Cap
666.16M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,667,163
P/E Ratio
-
Beta
2.88
1-Year Change
-44.38%
Shares Outstanding
649,911,648
Next Earnings Date
Aug 30, 2022
What is your sentiment on Mesoblast?
or
Market is currently closed. Voting is open during market hours.

Mesoblast Ltd News

Mesoblast Ltd Analysis

  • Markets Limp Towards Yellen’s Friday Speech
    • ByIG-

    The DXY US dollar index gained 0.2%The Kiwi dollar was the best performing G-10 currency gaining 0.4%The Aussie was basically flat on the session holding US$0.7612WTI oil...

  • QuickView: Mesoblast

    Mesoblast’s (MSB.AX) current valuation assumes a high probability of success for its stem cell technology, but it does hold the leadership position in this field. A proposed...

Mesoblast Ltd Company Profile

Mesoblast Ltd Company Profile

Employees
83
Market
Australia

Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • whys this company worth so much more on the NASDAQ?
    0
    • 1meso = 5msb
      0
    • Daniel Ma how does that work?
      0
    • No it is 4 Australian MESO stock = 1 NASDAQ MESO Stock.
      0
  • Rocket in 2 weeks
    2
    • $4.1 now from $3. This is still notbing compared to next few weeks :)
      1